Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

3 terminated out of 75 trials

Success Rate

89.3%

+2.7% vs benchmark

Late-Stage Pipeline

15%

11 trials in Phase 3/4

Results Transparency

12%

3 of 25 completed with results

Key Signals

3 with results89% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (15)
Early P 1 (2)
P 1 (5)
P 2 (8)
P 3 (3)
P 4 (8)

Trial Status

Completed25
Recruiting23
Unknown11
Not Yet Recruiting7
Withdrawn4
Terminated3

Trial Success Rate

89.3%

Benchmark: 86.6%

Based on 25 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT07737470Not Yet Recruiting

Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research

NCT07142239RecruitingPrimary

Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT03682419Completed

Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device

NCT00482794RecruitingPrimary

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

NCT05583305Enrolling By InvitationPrimary

Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome

NCT03684564Phase 2CompletedPrimary

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

NCT04262492RecruitingPrimary

International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

NCT07570511Not ApplicableNot Yet RecruitingPrimary

Point of Care Testing INR in Antiphospholipid Syndrome

NCT00198068Recruiting

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

NCT02450396Withdrawn

Pregnancy and Medically Assisted Conception in Rare Diseases

NCT07236762Phase 1Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07172022Phase 2WithdrawnPrimary

A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)

NCT07236801Phase 1Recruiting

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

NCT04402086Recruiting

Rheumatology Patient Registry and Biorepository

NCT03600636Not ApplicableCompletedPrimary

Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter

NCT06614270Not ApplicableRecruiting

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

NCT07301164Early Phase 1Not Yet Recruiting

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

NCT07212322Not ApplicableNot Yet Recruiting

A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

NCT05646394RecruitingPrimary

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

Scroll to load more

Research Network

Activity Timeline